Market Overview:
The global plasmid DNA market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for plasmid DNA products for research and therapeutic applications. In addition, the growing prevalence of cancer and other diseases is also contributing to the growth of this market. On the basis of type, HQ grade plasmid DNA dominates the global market, followed by GMP grade and non-GMP grade plasmid DNAs. The high quality and purity offered by HQ grade plasmids are driving their demand in research applications. However, GMP grade products are gaining traction due to their compliance with regulatory standards for use in clinical trials and commercial production. On the basis of application, cancers account for a major share of the global market for plasmid DNA products. This can be attributed to increasing funding towards cancer research as well as rising incidence rates of various types of cancers across different regions worldwide.
Product Definition:
Plasmid DNA Manufacturing is the process of creating plasmids, which are small pieces of DNA that can be easily manipulated in a lab. Plasmids are used in many different types of research, including gene therapy and genetic engineering.
HQ Grade Plasmid DNA:
Plasmid DNA is a single-stranded DNA molecule that carries a gene for the production of an extrachromosomal particle (Xenogen). Plasmid DNA can be used as an efficient cloning tool to introduce any desired gene into various types of cells. The most commonly used plasmids are those carrying the cauliflower mosaic virus 35S and beta-glucuronidase genes, which are useful in transfection procedures for producing recombinant proteins.
GMP Grade Plasmid DNA:
GMP grade plasmid DNA is a form of highly purified DNA used in the preparation of large quantities of high-quality plasmid DNA for further usage in gene cloning procedures. It is manufactured by the extraction and purification techniques using bioburden reduction technology which helps to maintain the purity level and yield more amount of final product with higher quality.
Application Insights:
In terms of application, the market is categorized into cancer, inherited disorders, viral infections, and others. In 2017, the cancer segment dominated the global plasmid DNA manufacturing market with a revenue share of over 40%. Plasmid pDNA is widely used in gene therapy for cancers due to its ability to deliver genes specifically to cells that need them. This has resulted in an increased demand for pDNA-based products across the globe.
The inherited disorders segment is expected to exhibit lucrative growth during the forecast period owing to rising awareness about inheritance of genetic diseases through carrier mothers and fathers.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, high investment in R&D and availability of skilled workforce. Moreover, increasing prevalence of chronic diseases coupled with rising healthcare expenditure by government entities is expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to factors such as low cost associated with plasmid DNA production and easy availability of raw materials such as bacteria and host cells which are sourced from local suppliers thereby reducing costs involved in Plasmid DNA Production Process (PDP). In addition, increase in awareness about advanced treatments for various diseases along with growing investments by major pharmaceutical companies for improving their position in respective markets will drive regional demand further.
Growth Factors:
- Increasing demand for plasmid DNA from the biotechnology and pharmaceutical industries for research and development purposes.
- Growing prevalence of genetic disorders and rising demand for gene therapy treatments are expected to drive the growth of the plasmid DNA market.
- Rising investment in R&D activities for novel drug discovery is also anticipated to propel the growth of this market in the near future.
- Technological advancements in plasmid DNA manufacturing processes are projected to offer lucrative opportunities for players operating in this market during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Plasmid DNA Manufacturing Market Research Report
By Type
HQ Grade Plasmid DNA, GMP Grade Plasmid DNA, Non-GMP Grade Plasmid DNA
By Application
Cancers, Inherited Disorders, Viral Infections, Others
By Companies
Cobra Bio, Richter-Helm, Eurogentec, Cell and Gene Therapy Catapult, VGXI, PlasmidFactory, Kaneka Corporation, Nature Technology Corporation, Waisman Biomanufacturing, FUJIFILM Diosynth Biotechnologies, LakePharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
154
Number of Tables & Figures
108
Customization Available
Yes, the report can be customized as per your need.
Global Plasmid DNA Manufacturing Market Report Segments:
The global Plasmid DNA Manufacturing market is segmented on the basis of:
Types
HQ Grade Plasmid DNA, GMP Grade Plasmid DNA, Non-GMP Grade Plasmid DNA
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancers, Inherited Disorders, Viral Infections, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Cobra Bio
- Richter-Helm
- Eurogentec
- Cell and Gene Therapy Catapult
- VGXI
- PlasmidFactory
- Kaneka Corporation
- Nature Technology Corporation
- Waisman Biomanufacturing
- FUJIFILM Diosynth Biotechnologies
- LakePharma
Highlights of The Plasmid DNA Manufacturing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- HQ Grade Plasmid DNA
- GMP Grade Plasmid DNA
- Non-GMP Grade Plasmid DNA
- By Application:
- Cancers
- Inherited Disorders
- Viral Infections
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Plasmid DNA Manufacturing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Plasmid DNA manufacturing is the process of creating plasmids from a DNA template. Plasmids are small, circular pieces of DNA that can be inserted into other cells to create new genetic combinations.
Some of the major players in the plasmid dna manufacturing market are Cobra Bio, Richter-Helm, Eurogentec, Cell and Gene Therapy Catapult, VGXI, PlasmidFactory, Kaneka Corporation, Nature Technology Corporation, Waisman Biomanufacturing, FUJIFILM Diosynth Biotechnologies, LakePharma.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Plasmid DNA Manufacturing Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Plasmid DNA Manufacturing Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Plasmid DNA Manufacturing Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Plasmid DNA Manufacturing Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Plasmid DNA Manufacturing Market Size & Forecast, 2018-2028
4.5.1 Plasmid DNA Manufacturing Market Size and Y-o-Y Growth
4.5.2 Plasmid DNA Manufacturing Market Absolute $ Opportunity
Chapter 5 Global Plasmid DNA Manufacturing Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Plasmid DNA Manufacturing Market Size Forecast by Type
5.2.1 HQ Grade Plasmid DNA
5.2.2 GMP Grade Plasmid DNA
5.2.3 Non-GMP Grade Plasmid DNA
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Plasmid DNA Manufacturing Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Plasmid DNA Manufacturing Market Size Forecast by Applications
6.2.1 Cancers
6.2.2 Inherited Disorders
6.2.3 Viral Infections
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Plasmid DNA Manufacturing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Plasmid DNA Manufacturing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Plasmid DNA Manufacturing Analysis and Forecast
9.1 Introduction
9.2 North America Plasmid DNA Manufacturing Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Plasmid DNA Manufacturing Market Size Forecast by Type
9.6.1 HQ Grade Plasmid DNA
9.6.2 GMP Grade Plasmid DNA
9.6.3 Non-GMP Grade Plasmid DNA
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Plasmid DNA Manufacturing Market Size Forecast by Applications
9.10.1 Cancers
9.10.2 Inherited Disorders
9.10.3 Viral Infections
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Plasmid DNA Manufacturing Analysis and Forecast
10.1 Introduction
10.2 Europe Plasmid DNA Manufacturing Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Plasmid DNA Manufacturing Market Size Forecast by Type
10.6.1 HQ Grade Plasmid DNA
10.6.2 GMP Grade Plasmid DNA
10.6.3 Non-GMP Grade Plasmid DNA
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Plasmid DNA Manufacturing Market Size Forecast by Applications
10.10.1 Cancers
10.10.2 Inherited Disorders
10.10.3 Viral Infections
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Plasmid DNA Manufacturing Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Plasmid DNA Manufacturing Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Plasmid DNA Manufacturing Market Size Forecast by Type
11.6.1 HQ Grade Plasmid DNA
11.6.2 GMP Grade Plasmid DNA
11.6.3 Non-GMP Grade Plasmid DNA
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Plasmid DNA Manufacturing Market Size Forecast by Applications
11.10.1 Cancers
11.10.2 Inherited Disorders
11.10.3 Viral Infections
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Plasmid DNA Manufacturing Analysis and Forecast
12.1 Introduction
12.2 Latin America Plasmid DNA Manufacturing Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Plasmid DNA Manufacturing Market Size Forecast by Type
12.6.1 HQ Grade Plasmid DNA
12.6.2 GMP Grade Plasmid DNA
12.6.3 Non-GMP Grade Plasmid DNA
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Plasmid DNA Manufacturing Market Size Forecast by Applications
12.10.1 Cancers
12.10.2 Inherited Disorders
12.10.3 Viral Infections
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Plasmid DNA Manufacturing Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Plasmid DNA Manufacturing Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Plasmid DNA Manufacturing Market Size Forecast by Type
13.6.1 HQ Grade Plasmid DNA
13.6.2 GMP Grade Plasmid DNA
13.6.3 Non-GMP Grade Plasmid DNA
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Plasmid DNA Manufacturing Market Size Forecast by Applications
13.10.1 Cancers
13.10.2 Inherited Disorders
13.10.3 Viral Infections
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Plasmid DNA Manufacturing Market: Competitive Dashboard
14.2 Global Plasmid DNA Manufacturing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Cobra Bio
14.3.2 Richter-Helm
14.3.3 Eurogentec
14.3.4 Cell and Gene Therapy Catapult
14.3.5 VGXI
14.3.6 PlasmidFactory
14.3.7 Kaneka Corporation
14.3.8 Nature Technology Corporation
14.3.9 Waisman Biomanufacturing
14.3.10 FUJIFILM Diosynth Biotechnologies
14.3.11 LakePharma
